

orney Docket No.: 10322.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yaver et al.

Confirmation No: 8946

Serial No.: 10/656,055

Group Art Unit: 1645

Filed: September 5, 2003

Examiner: Hines, Jana A.

For: Methods for Identifying Markers of Antimicrobial Compounds

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Mail Stop: Restriction Req. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

is being deposited with the United States Postal Service as first class mail in an envelope addressed to the address indicated above on November 22, 2005.

Seleste A. Buriani

(name of person mailing paper)

(signature of person mailing paper)

NOV 2 5 2005 BY Attorney Docket No. 10322.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yaver et al.

Confirmation No. 8946

Serial No.: 10/656,055

Group Art Unit: 1645

Filed: September 5, 2003

Examiner: Hines, Jana A.

For: Methods for Identifying Antimicrobial Compounds

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

This paper is being filed in response to the Office Action mailed November 3, 2005, that required Applicant to identify a single gene or nucleic acid to be searched in order for the election to be fully responsive. In the communication of August 12, 2005, Applicant elected the invention of Group I with traverse. Claims 1, 11, 27, 34, 36 and 42-43 read on the elected subject matter.

Applicant hereby selects the gene yerQ with accession number BG12843.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response to the restriction requirement.

Date: November 22, 2005

(14 4/4)

Respectfully submitted,

Robert L. Starnes, Ph.D.

Reg. No. 41,324

Novozymes Biotech, Inc.

1445 Drew Avenue Davis, CA 95616

(530) 757-4715